You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. AAV2-ASPA-Based Metabolic Intervention for Alzheimer's Disease

    SBC: ASKLEPIOS BIOPHARMACEUTICAL, INC.            Topic: NIA

    Abstract We propose to initiate preclinical development of a gene therapeutic targeted to Alzheimer's Disease. The World Health Organization's and Alzheimer's Disease International's report on Dementia (2012) recognizes that the global burden of AlzheimerDisease is forecast to worsen significantly with prevalence predicted to double every 20 years. Interventions that could prov ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. A biomarker of aging as a predictor of kidney transplant function

    SBC: HEALTHSPAN DIAGNOSTICS, LLC            Topic: NIA

    ABSTRACT The number of kidney transplant candidates on the waiting list continues to increase each year, while the number of kidney donations remains stagnant. The enduring donor shortage compels clinicians to use kidneys from marginal donors, referred toas expanded criteria donors (ECD). ECD kidneys, obtained primarily from older donors, have a higher risk of delayed graft function and graft loss ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Affinity Capture Peptides for Clinical Mass Spectrometric Assays in Plasma

    SBC: AFFINERGY, LLC            Topic: NIGMS

    DESCRIPTION (provided by applicant): We will develop the first assay for multiplexed combinations of all 14 Bone Morphogenetic Proteins. Immunoassays are the gold standard for measuring proteins in clinical samples. However these antibody- based tests neither quantitate protein analyte variants, nor multiplex across large numbers of superfamily members. In addition, the availability of polyclona ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. A High-Performance Quiet Gradient Coil for High-field Whole-body MRI

    SBC: DOTY SCIENTIFIC, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Preliminary data demonstrate that a radically different approach to MRI gradient coil design permits substantial advantages in all respects; especially in short, high-field magnets - higher gradient strength, reduced acoustic noise, and reduced nerve stimulation. A major advance in whole-body MRI gradient coil technology would be of fundamental benefit to the f ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  5. A Millimeter-wave Tunable Cavity for Ultra-sensitive Solids and Liquids DNP-NMR at Low Budget

    SBC: DOTY SCIENTIFIC, INC.            Topic: NIA

    ? DESCRIPTION (provided by applicant): NMR is probably the most powerful and widely used analytical technique for structure determination and function elucidation of molecules of all types, but it suffers from low sensitivity, particularly for insoluble biological macromolecules. Dynamic Nuclear Polarization (DNP) with Magic Angle Spinning (MAS) has recently demonstrated S/N gains exceeding t ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. A Multivalent Lyme Disease Vaccine Targeting Tick-Host-Pathogen Interactions

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    DESCRIPTION provided by applicant This proposal seeks to develop a novel vaccine against Lyme disease by targeting Ixodes scapularis proteins critical for Borrelia burgdorferi transmission from the tick to mammalian host Earlier work has identified four tick proteins Salp TRE tHRF and TSLPI that facilitate different steps of spirochete transmission and immunity against these protein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. A novel therapeutic approach for Acute Lung Injury/ARDS

    SBC: BIOMARCK PHARMACEUTICALS, LTD            Topic: NHLBI

    DESCRIPTION (provided by applicant): The objective of the proposed project is to advance the development of novel peptides targeting MARCKS (Myristoylated Alanine-Rich C Kinase Substrate) protein as platform drug molecules for the treatment of Acute Lung Injury (ALI) and its more severe form, Acute Respiratory Distress Syndrome (ARDS), thereby providing the first pharmacologic therapeutic for this ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. A Novel Treatment in a Bioterrorism Model of Pneumonic Plague Targets A1 ARs

    SBC: ENDACEA, INC            Topic: N/A

    DESCRIPTION (provided by applicant): Yersinia pestis (Y. pestis), the causative agent of plague, is a Gram-negative bacillus that is classified as a Category A pathogen by the Centers for Disease Control and a logical choice as a biological weapon. It has the potential to generate mass casualties and initiate a global epidemic of pneumonic plague. A major virulence factor for Y. pestis is endotoxi ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  9. Antivirals Targeting Flavivirus Envelope Proteins

    SBC: L2 DIAGNOSTICS LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this project is to develop therapeutic antivirals to treat life-threatening flavivirus infections. Enfuvirtide, a clinically successful peptide HIV fusion inhibitor, is the prototype for a new class of antivirals that inhibit viral envelope protein structural rearrangements essential for viral entry into host cells. In preliminary experiment ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  10. Antivirals Targeting Flavivirus Envelope Proteins

    SBC: L2 DIAGNOSTICS LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this project is to develop therapeutic antivirals to treat life-threatening flavivirus infections. Enfuvirtide, a clinically successful peptide HIV fusion inhibitor, is the prototype for a new class of antivirals that inhibit viral envelope protein structural rearrangements essential for viral entry into host cells. In preliminary experiment ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government